This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Systematic analysis of histone acetylation regulators across human cancers
BMC Cancer Open Access 08 August 2023
-
Acute Promyelocytic Leukemia: A History over 60 Years—From the Most Malignant to the most Curable Form of Acute Leukemia
Oncology and Therapy Open Access 05 February 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Santoro F, Botrugno OA, Dal Zuffo R, Pallavicini I, Matthews GM, Cluse L et al. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 2013; 121: 3459–3468.
Matthews GM, Mehdipour P, Cluse LA, Falkenberg KJ, Wang E, Roth M et al. Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood 2015; 126: 2392–4203.
Heideman MR, Wilting RH, Yanover E, Velds A, de Jong J, Kerkhoven R et al. Dosage dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood 2013; 121: 2038–2050.
Ropero S, Esteller M . The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1: 19–25.
Yang WM, YaoYL, Sun JM, Davie JR, Seto E . Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J Biol Chem 1997; 272: 28001–28007.
Welch JS, Yuan W, Ley TJ . PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice. J Clin Invest 2011; 121: 1636–1645.
Westervelt P, Lane AA, Pollock JL, Oldfather K, Holt MS, Zimonjic DB et al. High penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood 2003; 102: 1857–1865.
Malvaez M, McQuown SC, Rogge GA, Astarabadi M, Jacques V, Carreiro S et al. HDAC3- selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci USA 2013; 110: 2647–2652.
Robers MB, Dart ML, Woodroofe CC, Zimprich CA, Kirkland TA, Machleidt T et al. Target engagement and drug residence time can be observed in living cells with BRET. Nat Commun 2015; 6: 1–10.
Corces-Zimmerman MR, Majeti R . Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. Leukemia 2014; 28: 2276–2282.
Villa R, Morey L, Raker VA, Buschbeck M, Gutierrez A, De Santis F et al. The methyl CpG binding protein MBD1 is required for PML-RARalpha function. Proc Natl Acad Sci USA 2006; 103: 1400–1405.
Acknowledgements
Work in SM’s lab was supported by EC (4D Cell Fate), AIRC (IG13), CNR (Epigen Flagship Project). PM was a recipient of Fondazione Italiana per la ricerca sul cancro (FIRC) fellowship. We thank Roberto Dal Zuffo, Isabella Pallavicini and Alessia Schirripa for technical assistance.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Mehdipour, P., Santoro, F., Botrugno, O. et al. HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia. Leukemia 31, 995–997 (2017). https://doi.org/10.1038/leu.2017.3
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.3
This article is cited by
-
Systematic analysis of histone acetylation regulators across human cancers
BMC Cancer (2023)
-
Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα
Cell Death & Differentiation (2023)
-
Chemogenomics analysis of drug targets for the treatment of acute promyelocytic leukemia
Annals of Hematology (2020)
-
Acute Promyelocytic Leukemia: A History over 60 Years—From the Most Malignant to the most Curable Form of Acute Leukemia
Oncology and Therapy (2019)